​

Enveric Biosciences Stock (NASDAQ:ENVB)

ForecastOwnershipFinancialsChart
Enveric Biosciences by TradingView

Previous Close

$1.31

52W Range

$1.25 - $17.64

50D Avg

$1.42

200D Avg

$2.99

Market Cap

$829.85K

Avg Vol (3M)

$158.64K

Beta

1.13

Div Yield

$15.75K

ENVB Company Profile

Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

6

IPO Date

May 04, 2015

Website

ENVB Performance

ENVB Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-8.77M$-9.63M$-16.45M
Net Income$-12.13M$-9.57M$-17.29K
EBITDA$-8.57M$-9.23M$-16.85M
Basic EPS$-36.24$-228.48$-97.08
Diluted EPS$-36.24$-228.48$-97.08

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
SCNIScinai Immunotherapeutics Ltd.
ZVSAZyVersa Therapeutics, Inc.
SPRCSciSparc Ltd.
JSPRJasper Therapeutics, Inc.
ONCOOnconetix, Inc.
SLXNSilexion Therapeutics Ltd.
INDPIndaptus Therapeutics, Inc.